LGD-4033 vs SLU-PP-332
Moderate Research vs Emerging
avoid Mechanism-based · 53% Both LGD-4033 and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
LGD-4033 SLU-PP-332
Weight 338.25 Da 290.32 Da
Half-life ~24-36 hours Under investigation (no human PK data)
Chain — Non-peptide small molecule
Type Nonsteroidal selective androgen receptor modulator (C14H12F6N2O) Synthetic ERR agonist
Key Benefits
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
SLU-PP-332
01 Exercise mimetic effects without physical activity
02 12% weight loss in 28 days
03 70% increased endurance
04 25% enhanced fatty acid oxidation
05 Improved insulin sensitivity
06 Reduced hepatic steatosis
07 Cardiac protection
08 Reversal of age-related mitochondrial dysfunction
Dosing Protocols
LGD-4033
5-10 mg/day / Once daily (oral)
SLU-PP-332
NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP) / Research only - not approved for human use
Standard Metabolic Protocol 50 mg/kg (animal dosing) Twice daily
Acute Exercise Enhancement 50 mg/kg (animal dosing) Single dose 1 hour pre-exercise
Extended Treatment 50 mg/kg (animal dosing) Twice daily for 4-8 weeks
Side Effects
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
SLU-PP-332
Animal studies show favorable safety with no severe effects at therapeutic doses
Well-tolerated in rodents and canines
No liver, kidney, or cardiac toxicity documented
No lean mass loss
Does not suppress hormones or act as stimulant
Minor plasma cholesterol and liver enzyme changes in some studies
Contraindications
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
NOT FOR HUMAN USE - no approved human dose
No human clinical trials conducted
Potential interaction with diabetes medications
Research Evidence
LGD-4033 SLU-PP-332
Status Moderate Research Emerging
References 5 studies 4 studies
Latest 2018 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.